China NMPA Medical Device Review Center Issues Notice On The Release Of Clinical Evaluation Recommended Paths For Products In The Medical Device Classification Catalog (2024 Supplement) – Notice No. 11 Of 2024

In order to further guide applicants in determining the specific clinical evaluation paths for their registration, the Medical Device Review Center has issued a notice for the release of clinical evaluation recommended paths for a new batch of specific products. This is based on the 2022 notices, “Notice on the Release of Clinical Evaluation Recommended Paths for Products Related to Subcategories 11, 12, 13, 14, 15, 17, and 22 of the Medical Device Classification Catalog (2022 Notice No. 20)”, “Notice on the Release of Clinical Evaluation Recommended Paths for Products Related to Subcategories 02, 03, 05, 06, 16, 18, and 20 of the Medical Device Classification Catalog (2022 Notice No. 24)”, and “Notice on the Release of Clinical Evaluation Recommended Paths for Products Related to Subcategories 01, 04, 07, 08, 09, 10, 19, and 21 of the Medical Device Classification Catalog (2022 Notice No. 30)”.

These new recommendations are based on the latest developments in product research and application, scientific research achievements in clinical evaluation regulation, and practical work in technical review. For more information, please contact info@bradyknowsmedical.com.